Table 1.
Baseline Characteristics (N = 294).
Table 2.
Type of COVID-19 vaccination (N = 849).
Table 3.
Both solicited and unsolicited adverse events within 7 days and after 7 days post-vaccination.
Fig 1.
Both solicited and unsolicited adverse events within 7 days post-vaccination.
Solicited adverse events within 7 days and unsolicited adverse events after 7 days post-vaccination, graded according to CTCAE v5.0.
Table 4.
Adverse events of COVID-19 vaccine by current treatment status.
Table 5.
Logistic regression of the association between demographics, clinical factors and the occurrence of any grade adverse events after 1st dose of COVID-19 vaccine (92.9% AstraZeneca).